A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma
Clinical Cancer Research, 07/05/2012
Alsina M et al. – Escalated dosing of carfilzomib on a schedule of 2 consecutive days for 3weeks of a 4–week cycle was tolerable and showed promising activity. This dose regimen has been selected for ongoing and future clinical studies, including PX–171–003A1 and the pivotal trial ASPIRE.